Rekha Gohel, MD
Geriatric Medicine · Freehold, NJNPI 1679653992
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations.
Across 159 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$330
- E.r. Squibb & Sons, L.L.C.$277
- Novo Nordisk$197
- Bayer$156
- Sumitomo Pharma America, Inc.$154
- Lilly USA, LLC$143
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,029100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $330 |
| E.r. Squibb & Sons, L.L.C. | 5 | $277 |
| Novo Nordisk | 11 | $197 |
| Bayer | 8 | $156 |
| Sumitomo Pharma America, Inc. | 10 | $154 |
| Lilly USA, LLC | 9 | $143 |
| Amgen | 9 | $137 |
| Silk Road Medical, Inc. | 1 | $122 |
| BD | 1 | $121 |
| Boehringer Ingelheim | 6 | $89 |
| Eisai Inc. | 5 | $87 |
| Phathom Pharmaceuticals, Inc. | 6 | $87 |
| Merck | 6 | $84 |
| Lundbeck LLC | 5 | $75 |
| Acadia Pharmaceuticals Inc | 2 | $74 |
| Abbott | 4 | $73 |
| GSK | 5 | $73 |
| Amarin Pharma, Inc. | 5 | $69 |
| Exact Sciences | 3 | $69 |
| Novartis | 5 | $67 |
| Life Molecular Imaging Ltd | 3 | $65 |
| Corium, LLC | 5 | $59 |
| Pfizer | 4 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Johnson & Johnson | 3 | $40 |
| Avanir Pharmaceuticals, Inc. | 3 | $39 |
| Mylan Specialty L.p. | 2 | $35 |
| Vivus LLC | 2 | $27 |
| AbbVie | 2 | $27 |
| Radius Health, Inc. | 2 | $24 |
| Boston Scientific | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Bausch Health US, LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Biogen | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,029 in reported general payments places this provider in the 85th percentile of 165 geriatric medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 488 | $192,880 |
| JanuviaSitagliptin Phosphate | 176 | $113,331 |
| JardianceEmpagliflozin | 138 | $100,328 |
| TradjentaLinagliptin | 134 | $87,507 |
| RybelsusSemaglutide | 44 | $57,476 |
| MyrbetriqMirabegron | 115 | $46,487 |
| OzempicSemaglutide | 45 | $42,600 |
| XareltoRivaroxaban | 109 | $37,935 |
| FarxigaDapagliflozin Propanediol | 41 | $35,856 |
| VascepaIcosapent Ethyl | 89 | $33,024 |
| GemtesaVibegron | 50 | $31,020 |
| ProcritEpoetin Alfa | 32 | $30,896 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $29,601 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $25,986 |
| ProliaDenosumab | 13 | $21,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Retacrit | $54 | $205,648518 claims |
| Boehringer IngelheimJardiance, Tradjenta | $89 | $187,835272 claims |
| MerckJanuvia | $84 | $113,331176 claims |
| Novo NordiskRybelsus, Ozempic | $197 | $100,07689 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Incruse Ellipta | $73 | $73,556161 claims |
| Johnson & JohnsonXarelto, Procrit | $40 | $68,831141 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $46,487115 claims |
| AstraZenecaFarxiga | $330 | $35,85641 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $154 | $31,02050 claims |
| AbbVieLinzess, Creon | $27 | $24,06945 claims |
| AmgenProlia | $137 | $21,24713 claims |
| NovartisEntresto | $67 | $8,23721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 geriatric medicine providers in New Jersey.
Other geriatric medicine in Freehold
- Albert RiddleHaworth$524K
- Gamil MakarClifton$82K
- Joshua Shua HaimManchester$45K
- Pradip ShahWest Caldwell$27K
- Gregorio GuillenPerth Amboy$8K
- Ketankumar VaidyaEdison$8K
- Cheng-An MaoClifton$8K
- Theresa RedlingLivingston$7K
- Sarita RastogiHackensack$7K
- Leslie FeiginDenville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.